5-hydroxytryptamine receptor 7 activity modulators and their method of use

Patent metadata

Field	Value
Publication number	US-12503458-B2
Application number	US-202318544952-A
Country	US
Kind code	B2
Filing date	Dec 19, 2023
Priority date	Mar 11, 2013
Publication date	Dec 23, 2025
Grant date	Dec 23, 2025

Abstract

Pharmaceutical compositions of the invention comprise functionalized lactone derivatives having a disease-modifying action in the treatment of diseases associated with dysregulation of 5-hydroxytryptamine receptor 7 activity.

First claim

What is claimed is:

1 . A compound selected from the group consisting of:
3,3-diethyl-5-(2-(4-(p-tolyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one; 3,3-diethyl-5-(2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one; 3,3-diethyl-5-(2-(4-phenylpiperazin-1-yl)ethyl)dihydrofuran-2(3H)-one; 3,3-diethyl-5-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)dihydrofuran-2(3H)-one; 3-(2-(4-phenylpiperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-1-one; 3-(2-(4-(2-hydroxyphenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-1-one; 3-(2-(4-(pyridin-2-yl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-1-one; 3-(2-(4-(4-chlorophenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.5]decan-1-one; 3-(2-(4-(2-isopropylphenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.4]nonan-1-one; and 3-(2-(4-(2-morpholinophenyl)piperazin-1-yl)ethyl)-2-oxaspiro[4.4]nonan-1-one; or a pharmaceutically acceptable salt thereof.

2 . A pharmaceutical composition comprising a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable carriers.

3 . A method of treating a disease that involves dysregulation of the 5-hydroxytryptamine receptor 7 (5-HT 7 ) in a patient in need thereof, wherein said method comprises administering to a patient in need thereof an effective amount of a compound according to claim 1 , or a pharmaceutically acceptable salt thereof, and
wherein the disease is circadian rhythm disorder, depression, schizophrenia, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, sleep disorder, anxiety, seasonal affective disorder, or bipolar disorder.

4 . A method of treating a disease that involves dysregulation of the 5-hydroxytryptamine receptor 7 (5-HT 7 ) in a patient in need thereof, wherein said method comprises administering to a patient in need thereof an effective amount of a composition according to claim 2 , or a pharmaceutically acceptable salt thereof, and
wherein the disease is circadian rhythm disorder, depression, schizophrenia, migraine, neuropathic pain, peripheral pain, allodynia, thermoregulation disorder, learning disorder, memory disorder, sleep disorder, anxiety, seasonal affective disorder, or bipolar disorder.

5 . The method of claim 3 , wherein the at least one compound is administered in a composition further comprising at least one excipient.

Assignees

• Univ Temple

Inventors

• Canney Daniel J
• Blass Benjamin E
• Gao Rong
• Abou-Gharbia Magid

Classifications

• C07D307/33

  in position 2, the oxygen atom being in its keto or unsubstituted enol form · CPC title

• C07D307/94

  spiro-condensed with carbocyclic rings or ring systems, e.g. griseofulvins · CPC title

• C07D405/06

  linked by a carbon chain containing only aliphatic carbon atoms · CPC title

• A61P9/12

  Antihypertensives · CPC title

• A61P3/00

  Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00) · CPC title